Alzheimer's Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Alzheimer's Disease stocks.

Alzheimer's Disease Stocks Recent News

Date Stock Title
Nov 7 NXL (NXL) - Analyzing Nexalin Technology's Short Interest
Nov 7 ITCI Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress
Nov 7 LGND Ligand: Q3 Earnings Snapshot
Nov 7 LGND Ligand Pharmaceuticals beats Q3 top and bottom line estimates
Nov 7 LGND Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
Nov 7 AMLX Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results
Nov 7 AMED Amedisys Non-GAAP EPS of $1.00 misses by $0.17, revenue of $587.7M misses by $13.49M
Nov 7 AMED Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say
Nov 7 AMED Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates
Nov 6 AMED Amedisys: Q3 Earnings Snapshot
Nov 6 AMED Amedisys Reports Third Quarter 2024 Financial Results
Nov 6 ABOS Acumen Pharmaceuticals to Participate in the UBS Global Healthcare Conference
Nov 6 LGND Ligand Pharmaceuticals Q3 2024 Earnings Preview
Nov 6 ABOS Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality
Nov 6 ITCI Intra-Cellular bolsters Caplyta data with another Phase III win
Nov 6 AVXL Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval Scenario
Nov 5 ABOS Acumen Pharmaceuticals to Report Third Quarter Results on Nov. 12, 2024
Nov 5 AXSM Analysts Estimate Axsome Therapeutics (AXSM) to Report a Decline in Earnings: What to Look Out for
Nov 5 AMED Final Push For Amedisys As UnitedHealth Awaits Regulatory Clearance
Nov 5 ITCI Intra-Cellular meets main goal in late stage trial for its schizophrenia treatment
Alzheimer's Disease

Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60–70% of cases of dementia. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care, and behavioural issues. As a person's condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.The cause of Alzheimer's disease is poorly understood. About 70% of the risk is believed to be genetic with many genes usually involved. Other risk factors include a history of head injuries, depression, or hypertension. The disease process is associated with plaques and tangles in the brain. A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes. Initial symptoms are often mistaken for normal ageing. Examination of brain tissue is needed for a definite diagnosis. Mental and physical exercise, and avoiding obesity may decrease the risk of AD; however, evidence to support these recommendations is not strong. There are no medications or supplements that have been shown to decrease risk.No treatments stop or reverse its progression, though some may temporarily improve symptoms. Affected people increasingly rely on others for assistance, often placing a burden on the caregiver; the pressures can include social, psychological, physical, and economic elements. Exercise programmes may be beneficial with respect to activities of daily living and can potentially improve outcomes. Behavioural problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit with an increased risk of early death.In 2015, there were approximately 29.8 million people worldwide with AD. It most often begins in people over 65 years of age, although 4% to 5% of cases are early-onset Alzheimer's which begin before this. It affects about 6% of people 65 years and older. In 2015, dementia resulted in about 1.9 million deaths. It was first described by, and later named after, German psychiatrist and pathologist Alois Alzheimer in 1906. In developed countries, AD is one of the most financially costly diseases.

Browse All Tags